AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738
D5336C00001
Phase 2 small_molecule active
Quick answer
AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738 for Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active